Inhibition of AKT with the orally active allosteric AKT inhibitor, MK-2206, sensitizes endometrial cancer cells to progestin.

por Alok Pant, Irene I Lee, Zhenxiao Lu, Bo R Rueda, Julian Schink, J Julie Kim
Publicado 2012-01-01